Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibitionGabrielle S. Wong, Adam J. Bass, Shaunt Fereshetian et al.|Nature Medicine|2018Cited by 282
Epithelial PD-L2 Expression Marks Barrett's Esophagus and Esophageal AdenocarcinomaSarah Derks, Adam J. Bass, Katie S. Nason et al.|Cancer Immunology Research|2015Cited by 139
Author Correction: Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibitionGabrielle S. Wong, Adam J. Bass, Jin Zhou et al.|Nature Medicine|2018Cited by 10
Supplementary Figure S2 from Epithelial PD-L2 Expression Marks Barrett's Esophagus and Esophageal AdenocarcinomaSarah Derks, Adam J. Bass, Katie S. Nason et al.|Unknown|2023Cited by 0
Supplementary Figure S1 from Epithelial PD-L2 Expression Marks Barrett's Esophagus and Esophageal AdenocarcinomaSarah Derks, Adam J. Bass, Katie S. Nason et al.|Unknown|2023Cited by 0